CG Oncology (CGON) Operating Margin (2023 - 2026)
CG Oncology's (CGON) quarterly Operating Margin came in at 6130.1% in Q1 2026, up 7503144.0% YoY from N/an in Q1 2025, and down 192.28% on a QoQ basis from 2097.33% in Q4 2025.
CG Oncology (CGON) Operating Margin (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Operating Margin data on file, last reported at 6130.1% in Q1 2026.
- Quarterly Operating Margin rose 7503144.0% year-over-year to 6130.1% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4238.99% (up 1606328.0% YoY) and the FY2025 annual result came in at 4722.13%, up 534512.0% from the prior year.
- Operating Margin retreated to 6130.1% in Q1 2026, from 2097.33% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 2097.33% in Q4 2025 to a low of 1935500.0% in Q4 2023.
- A 4-year average of 208244.27% and a median of 8344.08% in 2024 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2024 — Operating Margin surged 192715592 bps — and 2025, when it tumbled 7691409 bps.
- Tracing CGON's Operating Margin over 4 years: stood at 1935500.0% in 2023, then surged by 100 bps to 8344.08% in 2024, then surged by 75 bps to 2097.33% in 2025, then plunged by 192 bps to 6130.1% in 2026.
- The last three Operating Margin figures came in at 6130.1% (Q1 2026), 2097.33% (Q4 2025), and 3068.97% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | -7,467.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7,467.68% |
| Mar 31, 2026 | -6,130.10% |
| Dec 31, 2025 | -2,097.33% |
| Sep 30, 2025 | -3,068.97% |
| Mar 31, 2025 | -81,161.54% |
| Dec 31, 2024 | -8,344.08% |
| Sep 30, 2024 | -65,802.33% |
| Jun 30, 2024 | -23,290.99% |
| Mar 31, 2024 | -4,247.45% |
| Dec 31, 2023 | -1,935,500.00% |
| Sep 30, 2023 | -156,033.33% |
| Mar 31, 2023 | -5,010.82% |